Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Aphios Awarded United States Patent

Abstract:
Patent for Compositions and Methods for Inhibiting 5-Alpha Reductase

Aphios Awarded United States Patent

Woburn, MA | Posted on July 27th, 2010

Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-á Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (á) reductase enzyme.

5-á reductase is responsible for causing benign prostatic hyperplasia (BPH) and male pattern baldness (alopecia) in men as well as hirsutism (male-pattern body hair) in women. An estimated 50% of men above 50 in the United States have BPH that causes urinary hesitation and frequent urination and night time visits to the bathroom. The incidence of BPH increases to 60% for men over sixty, 70% for men above 70, 80% or men above 80 following an Arrhenius-type plot. BPH has been linked to the incidence of prostate cancer that is the most prevalent cancer among men; and the second leading cause of cancer death among men in the US.

More than 500,000 prostate cancer cases are diagnosed each year in the United States, 1 in 6 American males will develop prostate cancer and 300,000 die of prostate cancer each year.

This invention is utilized in Aphios' SuperCool™ Palmetto and Sperol™ products for several conditions including benign prostatic hyperplasia, prostatic cancer, hirsutism, acne, male pattern baldness, seborrhea, and other androgen hyperactivity diseases. The active pharmaceutical ingredient, finasteride, of Merck's Proscar® for BPH and Propecia® for male pattern baldness work by the same mechanism of 5-á reductase inhibition as SuperCool™ Palmetto and Sperol™, which are natural alternatives to these drugs with fewer side effects.

The source for the active pharmaceutical ingredients in both SuperCool™ Palmetto and Sperol™ is the Serenoa repens (Saw Palmetto) berry.

The therapeutic compositions of the invention were discovered using Aphios' patented SuperFluids™ CXF drug discovery technologies and manufactured using Aphios' patented SuperFluids™ CXP drug manufacturing technologies. These technologies ensure purity, increase extraction efficiency and overall yield, and are environmentally friendly. These technologies are also utilized in Aphios' Zindol® and SuperCool™ Gingerol products for nausea and vomiting, and Xantol™ and SuperCool™ St. John's products for emotional well-being, relaxed outlook, and positive moods.

Research leading to this invention was in part conducted under a SBIR grant 1R43 AT00321-01 from the National Center of Complementary and Alternative Medicine (NCCAM), National Institutes of Health (NIH). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of NCCAM and NIH.

####

About Aphios
Aphios®, www.aphios.com and www.SuperCoolHealth.com, is a “green” biotechnology company developing enabling technology platforms for improved drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety. Based on these platforms, we are developing enhanced therapeutic products for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and Central Nervous System (CNS) disorders.

For more information, please click here

Contacts:
Trevor P. Castor, Ph.D.
CEO
781-932-6933

Copyright © Aphios

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Ultracold atom waves may shed light on rogue ocean killers: Rice quantum experiments probe underlying physics of rogue ocean waves April 27th, 2017

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Govt.-Legislation/Regulation/Funding/Policy

Ultracold atom waves may shed light on rogue ocean killers: Rice quantum experiments probe underlying physics of rogue ocean waves April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Graphene holds up under high pressure: Used in filtration membranes, ultrathin material could help make desalination more productive April 24th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

New Product Nanoparticle preparation from Intertronics with new Thinky NP-100 Nano Pulveriser April 26th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Announcements

Ultracold atom waves may shed light on rogue ocean killers: Rice quantum experiments probe underlying physics of rogue ocean waves April 27th, 2017

Looking for the quantum frontier: Beyond classical computing without fault-tolerance? April 27th, 2017

Metal nanoparticles induced visible-light photocatalysis: Mechanisms, applications, ways of promoting catalytic activity and outlook April 27th, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Patents/IP/Tech Transfer/Licensing

Forge Nano 2017: 1st Quarter Media Update April 20th, 2017

Making Batteries From Waste Glass Bottles: UCR researchers are turning glass bottles into high performance lithium-ion batteries for electric vehicles and personal electronics April 19th, 2017

'Neuron-reading' nanowires could accelerate development of drugs for neurological diseases April 12th, 2017

Laser activated gold pyramids could deliver drugs, DNA into cells without harm: Microstructures create temporary pores in cells March 27th, 2017

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results April 27th, 2017

Nanoparticle vaccine shows potential as immunotherapy to fight multiple cancer types April 24th, 2017

Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress(TM) April 20th, 2017

Nano-SPEARs gently measure electrical signals in small animals: Rice University's tiny needles simplify data gathering to probe diseases, test drugs April 17th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project